Travere Therapeutics, Inc.
Travere Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for rare diseases, with commercial products in kidney and metabolic disorders. Its portfolio includes FILSPARI, Thiola, and Thiola EC, and it also develops earlier-stage candidates such as pegtibatinase.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercial kidney-disease therapy for adults with IgA nephropathy.
Commercial cystinuria treatments sold through specialty pharmacy channels.
Milestones, royalties, and related collaboration income from partners.
Tuotteet
Raportoitu · osuus liikevaihdosta- FILSPARI65,6 %
- Tiopronin Products18,0 %
- License16,4 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Travere sells primarily to patients with rare kidney and metabolic diseases, with prescribing driven by specialists such as nephrologists and urologists. Because these therapies are dispensed through direct-to-patient and specialty pharmacy channels, access support, reimbursement assistance, and adherence services are an important part of the customer relationship.
Adults with primary IgAN treated with FILSPARI through specialist prescribing and pharmacy support.
Patients with cystinuria treated with Thiola and Thiola EC to reduce cystine stone formation.
Nephrologists and urologists who diagnose, prescribe, and monitor rare-disease therapies.
Organizations that determine reimbursement, prior authorization, and patient access conditions.
Collaborators such as CSL Vifor that contribute milestones, royalties, and regional commercialization support.
Strategia
Travere’s strategy centers on commercializing FILSPARI in IgA nephropathy, defending and extending its rare-disease franchise, and supporting access through specialist-focused patient services. The company also seeks to advance pipeline assets such as pegtibatinase while using partnerships and third-party manufacturing to limit capital intensity.
FILSPARI is the core commercial growth driver and the main source of product revenue.
Thiola and Thiola EC remain important but face generic competition and pricing pressure.
Pipeline assets provide future growth beyond the current commercial portfolio.
Outsourcing reduces the need for owned manufacturing infrastructure and supports flexibility.
Maantiede
Travere is headquartered in the United States and generates most of its commercial activity there, where FILSPARI and Thiola are marketed and distributed. It also has international exposure through collaboration and regulatory arrangements tied to FILSPARI in Europe, which adds partner-driven revenue and geographic diversification.
Riskit
Travere depends heavily on successful commercialization of FILSPARI and on physician, patient, and payer acceptance in a specialized rare-disease market. The company also faces generic competition in Thiola products, clinical development risk in its pipeline, and supply-chain dependence on third-party manufacturers and CROs.
- Generic competition for Thiola productsVaikutus: KorkeaTodennäköisyys: Korkea
Approved generics can reduce volume and pricing in the cystinuria franchise.
Kohdistuu: Thiola and Thiola EC sales
- Commercialization risk for FILSPARIVaikutus: KorkeaTodennäköisyys: Kohtalainen
Revenue depends on physician uptake, payer coverage, and sustained market acceptance in IgAN.
Kohdistuu: Core product revenue
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Pipeline candidates may not achieve approval or may require additional studies.
Kohdistuu: Pegtibatinase and future candidates
- Third-party manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company outsources API, packaging, and commercial supply, limiting direct control.
Kohdistuu: Product supply and launch execution
- CRO and investigator dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Clinical timelines and data quality rely on external research partners.
Kohdistuu: Development programs
Kirjanpito
Harkinnanvaraiset erätFILSPARI collaboration income and partner milestones can be recognized at different times than product shipments.
Vaikutus: Can cause volatility in reported revenue and mix
R&D expense depends on estimates of patient enrollment, study progress, and vendor invoices.
Vaikutus: Can shift operating expense timing
Product cost includes provisions for excess and obsolete inventory, especially for specialty products.
Vaikutus: Affects gross margin and cost of goods sold
License agreements may include deferred revenue, milestones, and royalty streams that require judgment.
Vaikutus: Can materially affect non-product revenue
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
PTC Therapeutics, Inc
PTCT · Pharmaceutical Preparations
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Savara Inc
SVRA · Pharmaceutical Preparations
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Zevra Therapeutics, Inc
ZVRA · Pharmaceutical Preparations
Zevra Therapeutics is a U.S.-based rare-disease pharmaceutical company focused on developing, commercializing, and expanding therapies for small patient populations with high unmet need.
Palvella Therapeutics, Inc
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Päivitetty: 24.9.2026